Cybrexa Therapeutics
PrivateLast Round
Series B
Mar 10, 2021
Total Funding Raised
$48.4M
Company Overview
Cybrexa Therapeutics is a biotechnology company that develops oncology therapeutics using its proprietary alphalex platform for antigen-independent intracellular drug delivery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cybrexa Therapeutics Comparables
Compare Cybrexa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| pHLIP, Inc. | 86% | |
| Avacta Group | 83% | |
| AnexAPep Inc. | 79% | |
Cybrexa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 10, 2021 | ||||
| Grant | Jul 2, 2019 | ||||
| Series B Extension | Jun 20, 2019 | ||||
| Series B | Jun 6, 2017 |
Cybrexa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Capital | Series B |
| National Cancer Institute | Grant |
| Connecticut Innovations | Series B Extension, Series B |
| HighCape Capital | Series B, Series B Extension |
| NIH RADx | Grant |
| Elm Street Ventures | Series B |
| Cycle Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2025
Presented data at the ESMO 2025 conference.
- Mar 5, 2025
Promising preclinical data on Tumor-Selective PDCs presented at ESMO 2025.
Cybrexa Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cybrexa Therapeutics's valuation, stock price, and market status.